First Comprehensive Amyloid Imaging Solution1
When evaluating for Alzheimer’s disease and other causes of cognitive decline
Two major challenges for utilizing novel imaging biomarkers are limited access and low delivery reliability. Limited access results in the inability to offer this new service to communities and therefore imaging centers being unable to expand their clinical offerings and revenue.
Low reliability results in patient dissatisfaction due to rescheduling, which may damage the reputation between the imaging center and its referring physicians. Today, Siemens' PETNET Solutions operates the largest network of PET radiopharmaceutical manufacturing facilities for amyloid and other novel imaging biomarkers in the United States. This current network covers most of the high Alzheimer’s disease prevalence areas in the country.
The combination of more complex and highly sensitive production and purification processes for next-generation PET imaging biomarkers, demands the need for new production and purification techniques, as well as new manual and automated manufacturing steps. Addressing these manufacturing challenges, Siemens' PETNET solutions has standardized its equipment and training process across its entire production network to reduce the level of complexity in production. In addition, Siemens' PETNET Solutions has invested in redundant equipment for key processes to eliminate single points of failure. Finally Siemens' PETNET Solutions employs dedicated staff and a fully-integrated operational support infrastructure for the production of amyloid imaging biomarkers. As a result, Siemens' PETNET Solutions is able to offer imaging centers and hospitals a delivery reliability of 96 percent across the USA.
*Actual timing will depend on successful FDA inspection at each site.